EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Disposition of famotidine in renal insufficiency



Disposition of famotidine in renal insufficiency



Journal of Clinical Pharmacology 27(10): 782-787



The disposition of famotidine was evaluated in 18 patients; Group 1, mild renal insufficiency, [creatinine clearance (CLCR): 30-60 mL/min]; Group 2, moderate to severe renal insufficiency (CLCR: 10-30 mL/min); Group 3, end-stage renal disease requiring maintenance hemodialysis (anuric). Blood and urine samples were obtained over a 72-hour period. Plasma concentration-time data demonstrated biexponential decay. The terminal elimination half-life was prolonged in Group 3 (18.6 +/- 5.7 hr) compared with Groups 1 (9.3 +/- 2.3 hr) and 2 (9.7 +/- 1.7 hr), P less than .05. Steady-state volume of distribution ranged from 0.80 to 1.26 L/kg but did not differ among the groups. Total body clearance (CLp) and renal clearance were significantly lower in Groups 2 and 3 patients compared with Group 1 patients. Nonrenal clearance was not related to CLCR. The CLp correlated well with CLCR (CLp = 1.59 CLCR + 33.8, r = 0.830, P less than .05). These data indicate that dosage adjustment may be necessary in patients who have renal insufficiency.

(PDF same-day service: $19.90)

Accession: 005170835

Download citation: RISBibTeXText

PMID: 3429684

DOI: 10.1002/j.1552-4604.1987.tb02996.x



Related references

Famotidine disposition in children and adolescents with chronic renal insufficiency. Journal of Clinical Pharmacology 43(1): 7-14, 2003

The effect of famotidine on renal function in patients with renal insufficiency. British Journal of Clinical Pharmacology 24(3): 385-389, 1987

Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers. European Journal of Clinical Pharmacology 36(5): 517-520, 1989

Propafenone disposition in renal insufficiency and renal failure. Journal of Clinical Pharmacology 29(2): 112-113, 1989

Disposition of enalapril and enalaprilat in renal insufficiency. Kidney International. Supplement 20: S117-S122, 1987

Disposition and dose requirements of drugs in renal insufficiency. Seldin, D W And G Giebisch (Ed ) The Kidney: Physiology And Pathophysiology, Second Edition, Vols 1, 2 And 3 Xxxiii+1409p (Vol 1); Xxxiii+1463p (Vol 2); Xxxi+945p (Vol 3) Raven Press: New York, New York, Usa 3671-3696, 1992

Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharmaceutics & Drug Disposition 1(3): 133-140, 1980

Disposition of oral potassium in dogs with chronic renal insufficiency. Kidney International 19(1): 205, 1981

Disposition of azelastine and demethylazelastine in pts with hepatic dysfunction and renal insufficiency. Pharmaceutical Research (New York) 9(10 SUPPL ): S318, 1992

Ganciclovir disposition in patients with renal insufficiency implications for dose adjustment. Pharmacotherapy 11(3): 277, 1991

The disposition of amylobarbitone in patients with severe chronic renal insufficiency and a pharmacological effect of its metabolite. Ceylon Association for the Advancement of Science Proceedings of the Annual Session 26(PART 1): 27-28, 1970

Inter- and intra-individual variations on the disposition of piroxicam. Pharmacokinetics in healthy man and the patient with renal insufficiency. Pharmaceutica Acta Helvetiae 57(1): 20-26, 1982

Famotidine does not interfere with the disposition of theophylline in man comparison to cimetidine. Clinical Pharmacology & Therapeutics 39(2): 187, 1986

Disposition and metabolism of famotidine a potent h 2 receptor blocker in man. Federation Proceedings 43(3): ABSTRACT 2167, 1984

Influence of famotidine and cimetidine on the disposition of phenytoin and indocyanine green. Clinical Pharmacology & Therapeutics 39(2): 225, 1986